Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Researchers at Université de Montréal and McGill University have discovered a new multi-enzyme complex that reprograms metabolism and overcomes “cellular senescence,” when aging cells stop dividing.
In a new study, researchers have introduced DSER, a technique for identifying molecular targets for enhanced therapy in prostate cancer.
Scientists headed by the University of Michigan Rogel Cancer Center converted an immune cold cancer into one that responds to immunotherapy.
A new study reports the use of single-cell, force spectroscopy methods to probe biophysical and biomechanical kinetics of cancer cells.
Oncotarget published "Dynamic cellular biomechanics in responses to chemotherapeutic drug in hypoxia probed by atomic force spectroscopy" which reported that by exploiting single-cell, force spectroscopy methods, the authors probed biophysical and biomechanical kinetics of brain, breast, prostate, and pancreatic cancer cells with standard chemotherapeutic drugs in normoxia and hypoxia over 12-24 hours.
In our latest interview, AZoLifeSciences spoke to a team of researchers about their latest research which involved carrying out CRISPR/Cas9 in Space.
A new study analyzing the association between an individual's genetics (genotype) and their observable characteristics resulting from the interaction of genetics and the environment (phenotype), contributes new knowledge to the understanding of human complex traits and diseases.
Malignant tumor cells undergo mechanical deformation more easily than normal cells, allowing them to migrate throughout the body. The mechanical properties of prostate cancer cells treated with the most commonly used anti-cancer drugs have been investigated at the Institute of Nuclear Physics of the Polish Academy of Sciences in Cracow.
Scientists from the UK's University of Bath explore racemases - an important type of enzyme that is linked to certain cancers and other life-threatening diseases while also being critical to cell function - in a paper published in the prestigious journal Chemical Society Reviews. The scientists also propose new strategies for finding drugs that neutralize these enzymes.
Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the University of Pennsylvania and published online in Cell Press's iScience.
Oncotarget published "Ibuprofen disrupts a WNK1/GSK3β/SRPK1 protein complex required for expression of tumor-related splicing variant RAC1B in colorectal cells" which reported that although the molecular mechanism behind the antitumor properties of NSAIDs has been largely attributed to inhibition of cyclooxygenases , several studies have shown that the chemopreventive properties of ibuprofen also involve multiple COX-independent effects.
Bioengineers at the University of California San Diego and San Diego State University have discovered a key feature that allows cancer cells to break from typical cell behavior and migrate away from the stiffer tissue in a tumor, shedding light on the process of metastasis and offering possible new targets for cancer therapies.
Artificial intelligence can already scan images of the eye to assess patients for diabetic retinopathy, a leading cause of vision loss, and to find evidence of strokes on brain CT scans.
A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.
The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.
When compared to other groups, certain ethnic and racial groups tend to suffer more often, and fare worse, from common ailments.
Cancer cells are known for spreading genetic chaos. As cancer cells divide, DNA segments and even whole chromosomes can be duplicated, mutated, or lost altogether.
A researcher at the University of Tartu described new associations between Neandertal DNA and autoimmune diseases, prostate cancer and type 2 diabetes.
Opened in 2016, Manchester’s Stoller Biomarker Discovery Centre (SBDC) is a globally renowned, multi-million-pound precision medicine research facility.
Researchers at the Estonian Genome Center at the University of Tartu studied how people at high risk for breast, ovarian or prostate cancer respond to the feedback of genetic findings.